Nick Desai, the co-founder and CEO of Heal, announced he would step down on Tuesday. Scott Vertrees, an advisor to the company, will become the company’s new CEO.
The companies will partner on development and commercialization of ARO-AAT, Arrowhead’s Phase II RNA-interference drug for alpha-1 antitrypsin-associated liver disease, a rare genetic disorder. An analyst wrote that the deal makes sense given Takeda’s position in the AAT-augmentation therapy market.
Kaiser Permanente opened its first medical school in Pasadena, California. Its first class of 50 students will have a mixture of in-person and virtual classes this year.